JP2024016024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016024A5 JP2024016024A5 JP2023172391A JP2023172391A JP2024016024A5 JP 2024016024 A5 JP2024016024 A5 JP 2024016024A5 JP 2023172391 A JP2023172391 A JP 2023172391A JP 2023172391 A JP2023172391 A JP 2023172391A JP 2024016024 A5 JP2024016024 A5 JP 2024016024A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- light chain
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 23
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 206010065687 Bone loss Diseases 0.000 claims 3
- 101000709472 Homo sapiens Sialic acid-binding Ig-like lectin 15 Proteins 0.000 claims 3
- 102100034361 Sialic acid-binding Ig-like lectin 15 Human genes 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000000217 endometrial squamous cell carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000566P | 2020-03-27 | 2020-03-27 | |
| US63/000,566 | 2020-03-27 | ||
| PCT/CN2021/083194 WO2021190622A1 (en) | 2020-03-27 | 2021-03-26 | Antibodies binding siglec15 and uses thereof |
| JP2022547787A JP7364315B2 (ja) | 2020-03-27 | 2021-03-26 | 抗体結合Ｓｉｇｌｅｃ１５及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547787A Division JP7364315B2 (ja) | 2020-03-27 | 2021-03-26 | 抗体結合Ｓｉｇｌｅｃ１５及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016024A JP2024016024A (ja) | 2024-02-06 |
| JP2024016024A5 true JP2024016024A5 (enExample) | 2024-04-04 |
Family
ID=77891322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547787A Active JP7364315B2 (ja) | 2020-03-27 | 2021-03-26 | 抗体結合Ｓｉｇｌｅｃ１５及びその使用 |
| JP2023172391A Pending JP2024016024A (ja) | 2020-03-27 | 2023-10-03 | 抗体結合Ｓｉｇｌｅｃ１５及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547787A Active JP7364315B2 (ja) | 2020-03-27 | 2021-03-26 | 抗体結合Ｓｉｇｌｅｃ１５及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11739147B2 (enExample) |
| EP (1) | EP4126938A4 (enExample) |
| JP (2) | JP7364315B2 (enExample) |
| KR (1) | KR102651263B1 (enExample) |
| CN (1) | CN115348970B (enExample) |
| AU (2) | AU2021240769B2 (enExample) |
| BR (1) | BR112022019129A2 (enExample) |
| CA (1) | CA3173201A1 (enExample) |
| IL (1) | IL296736B2 (enExample) |
| MX (1) | MX2022011951A (enExample) |
| PH (1) | PH12022552520A1 (enExample) |
| SA (1) | SA522440646B1 (enExample) |
| WO (1) | WO2021190622A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4126938A4 (en) * | 2020-03-27 | 2024-04-10 | Biosion, Inc. | ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES |
| WO2023093816A1 (zh) * | 2021-11-25 | 2023-06-01 | 诺纳生物（苏州）有限公司 | 抗Siglec-15抗体及其应用 |
| CN114134183B (zh) * | 2021-12-24 | 2022-12-06 | 广东南模生物科技有限公司 | 一种siglec15基因人源化动物模型的构建方法及应用 |
| CN114807052A (zh) * | 2022-06-07 | 2022-07-29 | 江苏亲科生物研究中心有限公司 | Siglec15单克隆抗体及其制备方法和用途 |
| EP4536714A1 (en) * | 2022-06-13 | 2025-04-16 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-siglec15 antibodies and uses thereof |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4604184B2 (ja) * | 2005-07-12 | 2010-12-22 | 独立行政法人産業技術総合研究所 | 新規糖鎖認識蛋白質及びその遺伝子 |
| US8168181B2 (en) * | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| BR112013008255A2 (pt) | 2010-10-05 | 2018-09-25 | Daiichi Sankyo Co Ltd | anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo |
| CA2848074A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
| KR20140138215A (ko) * | 2012-03-30 | 2014-12-03 | 다이이찌 산쿄 가부시키가이샤 | 신규 항 Ｓｉｇｌｅｃ-15 항체 |
| US9493562B2 (en) | 2012-07-19 | 2016-11-15 | Alethia Biotherapeutics Inc. | Anti-Siglec-15 antibodies |
| US20170129956A1 (en) * | 2014-06-18 | 2017-05-11 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta |
| KR102810368B1 (ko) * | 2015-11-10 | 2025-05-19 | 예일 유니버시티 | 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| EP3515478B1 (en) * | 2016-09-21 | 2024-02-28 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| CN108250296B (zh) * | 2018-01-17 | 2020-07-07 | 长春金赛药业有限责任公司 | 全人源抗人pd-l1单克隆抗体及其应用 |
| CN112638947B (zh) | 2018-08-30 | 2022-09-30 | 上海斯丹赛生物技术有限公司 | 用于治疗实体瘤的嵌合抗原受体细胞 |
| EP4126938A4 (en) * | 2020-03-27 | 2024-04-10 | Biosion, Inc. | ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES |
-
2021
- 2021-03-26 EP EP21774588.4A patent/EP4126938A4/en active Pending
- 2021-03-26 WO PCT/CN2021/083194 patent/WO2021190622A1/en not_active Ceased
- 2021-03-26 CN CN202180024369.4A patent/CN115348970B/zh active Active
- 2021-03-26 BR BR112022019129A patent/BR112022019129A2/pt unknown
- 2021-03-26 CA CA3173201A patent/CA3173201A1/en active Pending
- 2021-03-26 MX MX2022011951A patent/MX2022011951A/es unknown
- 2021-03-26 JP JP2022547787A patent/JP7364315B2/ja active Active
- 2021-03-26 KR KR1020227030409A patent/KR102651263B1/ko active Active
- 2021-03-26 AU AU2021240769A patent/AU2021240769B2/en active Active
- 2021-03-26 IL IL296736A patent/IL296736B2/en unknown
- 2021-03-26 PH PH1/2022/552520A patent/PH12022552520A1/en unknown
-
2022
- 2022-09-25 SA SA522440646A patent/SA522440646B1/ar unknown
- 2022-09-27 US US17/935,815 patent/US11739147B2/en active Active
-
2023
- 2023-05-31 AU AU2023203397A patent/AU2023203397A1/en active Pending
- 2023-06-23 US US18/340,367 patent/US20240002508A1/en active Pending
- 2023-10-03 JP JP2023172391A patent/JP2024016024A/ja active Pending